S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs

Invitae - NVTA Stock Forecast, Price & News

$2.55
-0.18 (-6.59%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.52
$2.74
50-Day Range
$2.03
$3.61
52-Week Range
$1.83
$18.44
Volume
5.67 million shs
Average Volume
10.88 million shs
Market Capitalization
$619.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.04

Invitae MarketRank™ Forecast

Analyst Rating
Hold
1.75 Rating Score
Upside/​Downside
215.4% Upside
$8.04 Price Target
Short Interest
Bearish
18.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.43) to ($1.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

486th out of 1,023 stocks

Medical Laboratories Industry

13th out of 24 stocks

NVTA stock logo

About Invitae (NYSE:NVTA) Stock

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Stock News Headlines

Is Invitae in Danger of Running Out of Money?
Why Shares of Invitae Rose 11% on Tuesday
Why Invitae Stock Is Crushing It Today
Invitae (NVTA) Q3 2022 Earnings Call Transcript
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) Share Price and News
Why Invitae Stock Is Jumping Today
See More Headlines
Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Company Calendar

Last Earnings
11/08/2022
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.04
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$2.80
Forecasted Upside/Downside
+215.4%
Consensus Rating
Hold
Rating Score (0-4)
1.75
Research Coverage
12 Analysts

Profitability

Net Income
$-379,010,000.00
Net Margins
-617.65%
Pretax Margin
-626.73%

Debt

Sales & Book Value

Annual Sales
$460.45 million
Book Value
$13.16 per share

Miscellaneous

Free Float
240,224,000
Market Cap
$619.38 million
Optionable
Optionable
Beta
1.61

Key Executives

  • Mr. Kenneth D. Knight (Age 61)
    Pres, CEO & Director
    Comp: $1M
  • Ms. Yafei Wen (Age 49)
    Chief Financial Officer
    Comp: $422.73k
  • Mr. Thomas R. BridaMr. Thomas R. Brida (Age 51)
    Gen. Counsel, Chief Compliance Officer & Sec.
    Comp: $425k
  • Dr. Robert L. Nussbaum M.D.Dr. Robert L. Nussbaum M.D. (Age 72)
    Chief Medical Officer
    Comp: $391.35k
  • Ms. Shelly D. GuyerMs. Shelly D. Guyer (Age 62)
    Chief Sustainability Officer
    Comp: $430.44k
  • Mr. Robert F. Werner (Age 49)
    Chief Accounting Officer & Principal Accounting Officer
  • Mr. Jackson J. Finks C.F.A.
    CFA, Director of Investor Relations & Strategic Fin.
  • Mr. Lee Bendekgey J.D. (Age 64)
    Chief Policy Officer
  • Glenn Medalle
    Head of Talent
  • Ms. Desarie French
    Chief Talent Officer













NVTA Stock - Frequently Asked Questions

Should I buy or sell Invitae stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 3 sell ratings and 9 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings
or view top-rated stocks.

What is Invitae's stock price forecast for 2023?

12 equities research analysts have issued 12-month target prices for Invitae's stock. Their NVTA share price forecasts range from $2.80 to $18.00. On average, they anticipate the company's stock price to reach $8.04 in the next twelve months. This suggests a possible upside of 215.4% from the stock's current price.
View analysts price targets for NVTA
or view top-rated stocks among Wall Street analysts.

How have NVTA shares performed in 2022?

Invitae's stock was trading at $15.27 at the beginning of the year. Since then, NVTA shares have decreased by 83.3% and is now trading at $2.55.
View the best growth stocks for 2022 here
.

When is Invitae's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NVTA earnings forecast
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) released its earnings results on Tuesday, November, 8th. The medical research company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.17. The medical research company had revenue of $133.54 million for the quarter, compared to analyst estimates of $132.80 million. Invitae had a negative net margin of 617.65% and a negative trailing twelve-month return on equity of 39.04%.

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (12.95%), Vanguard Group Inc. (8.90%), Sumitomo Mitsui Trust Holdings Inc. (7.34%), Fisher Asset Management LLC (1.30%), State of Michigan Retirement System (0.83%) and Polar Asset Management Partners Inc. (0.70%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends
.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $2.55.

How much money does Invitae make?

Invitae (NYSE:NVTA) has a market capitalization of $619.38 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($13.84) on an earnings per share basis.

How many employees does Invitae have?

The company employs 3,000 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (415) 374-7782 or via email at ir@invitae.com.

This page (NYSE:NVTA) was last updated on 12/7/2022 by MarketBeat.com Staff